Novo Nordisk to lay off 9,000 workers as new CEO aims to save $1.3B per year by late 2026

Novo Nordisk, under new CEO Maziar Mike Doustdar, is implementing a significant restructuring that includes 9,000 global layoffs, targeting $1.3 billion in annual savings by the end of 2026. This strategic move, aimed at addressing organizational complexity and enhancing focus on its core diabetes and obesity businesses amidst increased competition, will incur a one-off $1.3 billion cost. Consequently, the company has revised its 2025 operating profit growth outlook down from 10-16% to a range of 4-10%, reflecting the immediate financial impact of this initiative in a highly competitive market challenged by rivals like Eli Lilly's Zepbound and compounded medications.

Analysis

Novo Nordisk, under new CEO Maziar Mike Doustdar, is undertaking a significant corporate restructuring involving a 9,000-employee layoff to generate approximately $1.3 billion in annual savings by the end of 2026. This decisive action is a direct response to intensifying competitive pressures and a noted slowdown in sales growth. Specifically, Eli Lilly’s Zepbound has overtaken Novo's Wegovy in weekly U.S. prescriptions, and the market for compounded semaglutide has grown to a size reportedly “equal” to Novo’s own GLP-1 business. The restructuring carries a substantial near-term financial impact, with a one-off cost of $1.3 billion leading to a material downward revision of the 2025 operating profit growth outlook to a range of 4-10%, a sharp decrease from the prior 10-16% guidance. The strategic intent is to reduce organizational complexity and reallocate saved capital toward R&D and commercial execution in the core diabetes and obesity franchises to defend its market leadership. This move, implemented just one month into the new CEO's tenure, signals a clear strategic pivot and heightened urgency to realign the company's cost base and competitive posture.

Key Decisions for Investors

• Investors must immediately adjust 2025 financial models for Novo Nordisk to reflect the revised, lower operating profit growth guidance of 4-10%, factoring in the $1.3 billion one-off restructuring charge.
• The competitive landscape is a critical monitoring point; track weekly prescription data for Wegovy versus Eli Lilly's Zepbound and any regulatory actions impacting the compounded drug market, as these are primary drivers of Novo's strategic shift.
• While the restructuring aims for long-term efficiency, it introduces significant execution risk under new leadership, warranting close scrutiny of the company's ability to achieve targeted cost savings and effectively reinvest capital without disrupting core operations.